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Background: High Resolution Melting (HRM) Analysis is a validated, robust, low-cost, high throughput CF screening method. Here, we report the
development and retrospective evaluation of the diagnostic value of a novel multiplex HRM, genotyping and haplotyping method for CF prenatal
diagnosis (generic HRM/haplotyping).
Methods: 80 study samples from 20 carrier couples referred for PND (whole blood in EDTA and CVS or amniotic ﬂuid) were genotyped
retrospectively using the suggested protocol.
Results: All DNA samples (variable sources, extraction methods and unknown concentrations) were successfully ampliﬁed by the 1st and 2nd
round PCR. The Se, Sp, NPV and PPV for the generic HRM/haplotyping method are calculated at 100%.
Conclusions: This generic protocol for PND using HRM, facilitates the simultaneous analysis of DNA samples from various sources in a fast,
robust and efﬁcient way. It can be easily adapted and applied for any genetic condition.
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Cystic fibrosis (CF) (MIM#219700) is the second most
common autosomal recessive disorder in Greece after thalas-
semias. The carrier frequency is estimated to be approximately☆ Gene Symbol: CFTR.
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,.V. A3–4% of the general population with an incidence of about 1 in
2500–3500 live births [1]. Cystic fibrosis is caused by
mutations in the Cystic Fibrosis Transmembrane Conductase
Regulator (CFTR) gene. CFTR is located on chromosome
7q31.2, encoding a glycosylated transmembrane protein of
1480 amino acids. The gene has been identified in 1989 [2],
and since then more than 1800 disease causing variants have
been described [3]. The frequency and distribution of disease
causing variants show a clear ethnic and geographical
distribution. The frequency of the most common mutation
p.Phe508del (F508del, c.1521_1523delCTT) (CFTR reference
sequence NM_000492.3 and NG_016465.1) varies significantly
between ethnic groups, even between countries of close geographic
proximity. In Greece the frequency is estimated at ≈53% of CF
alleles, whereas in neighbouring Albania the frequency is ≈73%ll rights reserved.
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commonest mutation may vary from as high as 87.5% in
Denmark to 36.6% in Romania [1]. Regardless of the frequency,
p.Phe508del is always screened for, when testing for CFTR
mutations.
The typical presentation of CF includes progressive pulmonary
disease, pancreatic insufficiency, meconium ileus, liver disease
with advancing age and positive sweat chloride test [4]. Although
quality of life and expectancy have greatly improved over the past
decades for all CF patients, CF remains a severe and incurable
disease, therefore prenatal diagnosis (PND) is offered to all
couples when both members are known carriers of severe CF
mutations.
The Greek population has one of the highest rates of CFTR
mutation heterogeneity, making molecular diagnosis especially
difficult [5]. Due to the degree of heterogeneity the highest
detection rate that can be achieved by commercially available kits,
reaches less than 80% [6]. In order to achieve a higher detection
rate and since the Department of Medical Genetics (DMG) serves
as a reference laboratory, we have been performing exon scanning
using DGGE (Denaturing Gradient Gel Electrophoresis) followed
by bi-directional sequencing of all positive findings [2]. However
DGGE is a very laborious and time consuming methodology
which makes it incompatible with the increasing number of
samples being analysed. For these reasons, in the past three years,
we have changed our scanning methodology to High Resolution
Melting Analysis (HRM) using LightScanner® (Idaho Technol-
ogies, Utah, USA).
HRM is based on a fundamental property of DNA which is
melting. Themethod consists of PCR amplification of the fragment
in question, in the presence of a dsDNA intercalation fluorescent
dye (LCGreen® Plus, Idaho Technologies, Utah, USA). Following
PCR the samples are melted. Heating of the double helix, causes
the separation of the two strands creating a unique melting curve
pattern according to the composition of the fragment analysed.
Any change in the composition of the fragment will create a
different melting profile allowing the user to distinguish between
the variants [7]. HRM is an inexpensive, fast and robust method
for detecting sequence changes in genomic DNA.
In our laboratory HRM has been validated and is currently
being used as a routine method for screening the whole coding
sequence and flanking intronic regions of the CFTR gene. Since
the application of HRM for CFTR screening, we have analysed
more than 4000 samples with exceptional sensitivity and
specificity rates. The primers used are as published in the paper
from Montgomery et al. [8]. All positive findings are confirmed
by subsequent bi-directional sequencing. Samples that do not
clearly fall in the wild type genotype (borderline findings) are
re-analysed in a second HRM experiment and if necessary the
genotype is confirmed by sequencing.
A successful HRM experiment depends on primer (gene
scanning) and probe (genotyping) designs as well as DNAquantity
and quality. One major drawback of the method is that it requires
standardised DNA extraction and purification so that all samples
are finally dissolved in the same buffers to minimize ionic
differences that affect melting curves [9]. That signifies that the
use of samples from different sources (peripheral blood, amnioticfluid and chorionic villus samples), different extraction protocols
(salting out, manual extraction kits and robotic extraction
systems) or poor quality DNA (samples with impurities) in the
same experiment is prohibitive.
These limitations pose a serious problem in a diagnostics
laboratory that also serves as a reference laboratory for molecular
analysis of theCFTR gene. Our laboratory often receives not only
blood samples, but also already extracted DNA samples from
other laboratories in order to further analyse them. These samples
cannot be analysed in the same experiments and it is very difficult
to create batches of samples extracted in the same way since
each laboratory uses different DNA extraction protocols. When
providing diagnostic services each positive finding has to be
confirmed by two methods. Since we have switched from DGGE
analysis it is not feasible to use the old technology to analyse
these samples. Therefore the need arose for the establishment of a
second method, besides sequencing, to confirm the results.
These problems also apply to prenatal diagnosis where
ideally we want to analyse the family samples in one common
experiment. The prenatal diagnosis should be performed in a
manner where the findings are confirmed by two different
methods. At the same time the protocol used should allow for the
exclusion ofmaternal contamination of the sample used as well as
confirmation of paternity. In order to overcome the limitation
arising from extracted DNA quality and quantity, we have
developed and validated a multiplex HRM and STR analysis
protocol, which allows us to analyse consistently and with high
specificity, samples from variable sources extracted in different
ways, in the same experiment. Here we report, the development
and retrospective evaluation of the validity, diagnostic value and
accuracy of a novel multiplex haplotyping and HRM method for
CF prenatal diagnosis.
2. Materials and methods
2.1. Study samples
Peripheral blood samples were collected in EDTA contain-
ing tubes from 20 CF carrier couples, who were referred for
prenatal diagnosis (PND) to DMG (genotype combinations are
shown in Table 1) over a period of 10 years (2002–2012).
DNA was extracted from peripheral blood samples using
either Qiagen's QIAamp DNA Blood Mini Kit or MagAttract
DNABloodM48Midi Kit (Qiagen, Hilden, Germany) following
the manufacturer's instructions. Manual Salting Out method [10]
was used to extract DNA from blood samples which were
collected in 2003. Foetal samples were received at the DMG
following standard chorionic villus sampling (CVS) at 12–14
weeks of gestation or amniocentesis at 15–17 weeks of gestation.
DNA from CVS and AF samples was extracted by following
Qiagen's QIAamp DNA Blood Mini Kit protocol for tissue
extraction. In some cases DNA samples corresponding to foetal
tissue or cells were sent directly to the DMG for testing (Table 1).
All the foetal DNA samples from past PND cases were kept
under −80 °C. PND cases included in the study were analysed
retrospectively. Initially, diagnosis was achieved through stan-
dard validated laboratory procedures involving DGGE analysis.
Table 1
PND cases analysed in the retrospective study.
Case Mutations tested (legacy name — exon number) Date received (m/y) Case Mutations tested (legacy name — exon number) Date received (m/y)
1 p.Glu826Lys (E826K-14)
p.Phe508del (F508del-11)
3/2010 11 p.Arg74Trp (R74W-3)
p.Phe508del (F508del-11)
9/2003
2 c.489 + 1G N T (621 + 1G N T-intron 4)
p.Gly85Glu (G85E-3)
7/2003 12 p.Asn1303Lys (N1303K-24)
p.Asn1303Lys (N1303K-24)
7/2007
3 ⁎ p.Phe508del (F508del-11)
p.Tyr301Cys (Y301C-8)
1/2008 13 ⁎ p.Asn1303Lys (N1303K-24)
p.Phe508del (F508del-11)
5/2009
4 p.Trp496X (W496X-11)
p.Gly542X (G542X-12)
9/2005 14 p.Phe508del (F508del-11)
p.Phe305Val (F305V-8)
9/2006
5 ⁎ p.Gly542X (G542X-12)
p.Phe508del (F508del-11)
6/2004 15 p.Phe508del (F508del-11)
p.Phe508del (F508del-11)
9/2011
6 p.Phe508del (F508del-11)
p.Phe508del (F508del-11)
2/2002 16 c.489 + 1G N T (621 + 1G N T-intron 4)
p.Phe508del (F508del-11)
11/2003
7 p.Phe508del (F508del-11)
p.Phe508del (F508del-11)
3/2006 17 p.Phe508del (F508del-11)
c.3368-2A N G (3500-2A N G-intron 20)
4/2010
8 p.Gly542X (G542X-12)
p.Gly542X (G542X-12)
6/2012 18 p.Phe508del (F508del-11)
p.Phe508del (F508del-11)
8/2011
9 p.Phe508del (F508del-11)
c.3368-2A N G (3500-2A- N G-intron 20)
9/2008 19 p.Phe508del (F508del-11)
p.Phe508del (F508del-11)
8/2009
10 ⁎ p.Asn1303Lys (N1303K-24)
c.489 + 1G N T (621 + 1G N T-intron 4)
6/2008 20 ⁎ c.1393-1G N A (1525-1G N A-intron 10)
c.2988 + 1G N A (3120+ 1G- N A-intron 18)
6/2010
⁎ The cases marked with an asterisk (3,5,10,13 and 20) arrived in DGM as already extracted DNA. (GenBank P13569).
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ing and parallel haplotype analysis as previously described [11].
3.1. 1st round PCR reaction
A first 11-plex PCR reaction was optimized to simultaneously
amplify 9 CF exon targets (bearing the most common mutations
found in the Greek population) and 2 intragenic STR markers
labelled with FAM/TAMRA to facilitate subsequent fragment
analysis in an automatic sequencer (Supplementary data Table 1).
The 11-plex PCR allows us to analyse simultaneously PND cases
from families bearing different mutations. Primers for HRMwere
obtained from Montgomery et al. [8] (Supplementary data Table
1). Each 1st round of 20 μl multiplex PCR was performed using
Multiplex HotStart Taq (Qiagen, GmbH Germany) according to
the manufacturer's instruction, adding CF exon primers and IVS8
at a final concentration of 0.15 μM and D7S677 at 0.2 μM using
a touchdown PCR protocol ranging from 60 °C to 54 °C (PCR
and cycling conditions are shown in Supplementary data Tables 2
& 3).
3.2. 2nd round PCR
After the first touchdown PCR, a second round “nested”
PCR reaction was performed individually for each exon using
Idaho's LightScanner® Master Mix (Idaho Technologies) with
the same exon primers as used in the 1st round PCR. The PCR
products of the 1st round PCR reaction were diluted by 1/1000
(1 μl PCR product in 999 μl of DNase, RNase free ddH2O) and
2 μl of the diluted PCR product was used as a template for the
“nested” reactions. The total volume of the 2nd round PCR
reaction was 10 μl according to the LightScanner® Master Mix
instructions and was set up in Qiagen's PCR robotic system
QIAgility (Qiagen) (Supplementary data Tables 5 & 6). The
reaction was performed in Bio-Rad (Bio-Rad LaboratoriesCalifornia USA) compatible 96-well plates using the accompa-
nying sealing films. 2nd round PCR was overlaid with 25 μl
mineral oil (Sigma-Aldrich Corporation, St. Louis, MO). Before
and after PCR cycling the plates were centrifuged at 3000 rpm
for 2 min.
Exon 11 of CFTR gene (legacy exon 10) (CFTR reference
sequence NM_000492.3 and NG_016465.1) carries p.Phe508del
(c.1521_1523delCTT) which is the most common mutation
occurring in CF patients and is very often found in a homozygous
state. Exon 11 also includes a lot of non-disease causing
polymorphisms which in combination with p.Phe508del can
result in misinterpretation. For this reason, in order to detect it
specifically, in the second PCR reaction we also used an
unlabelled probe genotyping assay as previously described [12].
The conditions and cycling for the asymmetric 2nd round PCR
for exon 11 are shown in Supplementary data Tables 6 & 7.
4. Melting analysis
After the 2nd round PCR reaction the products were imaged
in a 96-well LightScanner (Idaho Technologies). PCR products
were melted by increasing the temperature from 60 to 98 °C at
a programmed rate of 0.1 °C/s with exposure set to automatic.
When the probe was included in the plate the starting melting
temperature was set at 50 °C. Melting curves were analysed
with commercial LightScanner software.
4.1. STR analysis
Haplotype scoring, through IVS8CA and D7S677 fragment
analysis, was facilitated by loading 1st round PCR products on
an automatic sequencer (MegaBACE 1000 capillary sequencer,
Amersham Pharmacia Biotech), following heat denaturation at
80 °C for 2 min. STR analysis is used to monitor maternal
contamination and to confirm paternity in the analysed PND
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from an affected/unaffected sibling or the couple's previously
terminated foetus, was available for simultaneous analysis.
4.2. Generic HRMPND protocol diagnostic performance analysis
To assess the diagnostic performance of the HRM PND
protocol, the sensitivity (Se), specificity (Sp), the false negative
(FN) and false positive (FP) rates were calculated through the
construction of Table 2. Genotypes obtained in the CVS and
AF samples through the application of standard and validated
laboratory diagnostic techniques (DGGE and sequencing) were
defined as the “true genotypes” and the genotypes achieved in
the same samples by the generic multiplex HRM PND protocol
were defined as the ‘test genotypes’. To facilitate and simplify
parameter calculations, sample genotypes were converted into
two categories: affected and unaffected. This step was taken
because AF and CVS genotypes can potentially correspond to
four categories: (i) wild type, (ii) heterozygous for the maternal
mutation, (iii) heterozygous for the paternal mutation, and
(iv) double heterozygote or homozygote (in cases where the
parents carry the same mutation). Hence, affected genotypes
correspond to double heterozygotes or homozygotes for a
mutation and unaffected genotypes correspond to wild type and
heterozygotes.
5. Results
5.1. 1st round and 2nd round PCR amplification and genotyping
efficiency
Using this generic protocol we, retrospectively, tested 20
prenatal diagnosis cases for CFTR gene mutations (genotype
combinations shown in Table 1) (a total of 76 samples). The
number of samples tested includes the mother–father–embryo
trio as well as previous children of the family, when this was
available. All target sequences were successfully amplified in
all samples analysed (76/76). Therefore the 1st round 11-plex
PCR and 2nd round ‘nested’ PCR demonstrate an amplification
efficiency of 100%.
Amplification of all targets was achieved in all study samples.
This demonstrates the method's robustness and flexibility, sinceTable 2
Construction used to calculate the diagnostic performance of the HRM PND
protocol.
Test genotypes
HRM PND
Affected Unaffected Total
Affected a (true positive) b (false positive) a + b
Unaffected c (false negative) d (true negative) c + d
Total a + c b + d N
Sensitivity (Se); proportion a / (a + c) negative predictive value; proportion d /
(c + d).
Specificity (Sp); proportion d / (b + d) positive predictive value; proportion a /
(a + b).
False negative (FN); proportion c / (a + c).
False positive (FP); proportion b / (b + d).DNA samples were extracted from different sources (amniotic
fluid cells, chorionic villus and peripheral blood) by application
of different extraction methods (automatic: Qiagen's MagAttract
DNA Blood Kit and manual: Qiagen's QIAamp DNA Blood
Mini Kit as well as Salting Out method) and were kept at−80 °C.
Amplification was also achieved in already extracted DNA
samples sent to our laboratory for analysis, without prior
knowledge of the methodology used for extraction. Supplemen-
tary data Figs. 1 to 9 show the HRM results for each exon and
Supplementary data Fig. 10 shows the haplotype analysis of one
of the PND cases.
5.2. Diagnostic efficiency of the generic HRM PND method
The HRM PND method is an efficient, robust diagnostic tool
as shown by the calculated diagnostic efficiency parameters. The
method exhibited a sensitivity and specificity of 100% with FP
and FN rates of 0% in genotyping a wide spectrum of mutations.
The results show that the method is very sensitive and specific in
genotyping archived samples from variable sources and different
extraction methods.
The samples tested, using this protocol harboured mutations in
nine different exons, most commonly identified in CF patients of
Greek origin. The protocol allows the simultaneous amplification
of different exons as well as two intragenic markers, for haplotype
analysis. It is very important to stress that the multiplexing of this
protocol allows all the PND cases in the laboratory to be analysed
in a single experiment without worrying about the genotype
combinations that each family carries.
6. Discussion
Since the implementation of a carrier screening programme
for thalassemias in Greece, cystic fibrosis became the most
common autosomal recessive disorder affecting young children.
Therefore it is extremely important to be able to offer accurate
carrier screening and prenatal diagnosis services. These services
should also be offered in a cost effective way since the national
health system cannot cover the expenses of a generalised
screening programme. The increasing awareness for CF testing,
has led to an increase of the samples being analysed. In order to
compensate for this increase we had to update our testing
methodologies and switch from DGGE analysis, which is labour
intensive and does not allow large scale analysis, to HRM.
HRM is a cost effective and robust method, showing the same
sensitivity and specificity to DGGE. The most important
advantage lies in the ability to perform large scale analysis in
minimum time. For example in each DGGE gel we can load 20
samples and the running time is approximately 16 h, whereas for
HRM each plate, containing 96 samples, can be analysed in
10 min. The timely molecular analysis is a key advantage, as in
some cases the samples being processed derive from couples in
the second trimester of pregnancy, mostly presenting with foetal
echogenic bowel findings. Given the high molecular heteroge-
neity of the Greek population, these couples are screened for the
entire CFTR coding sequence and if both parents are found
carriers, of CF causing mutations, prenatal diagnosis is offered.
Fig. 1. Flow chart of the suggested protocol.
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and each analysis, in a diagnostic setting, should be confirmed by
two methodologies there was a great need to develop a novel
protocol that allows the use of HRM technology in prenatal
diagnosis.
One major drawback of HRMmethod is that it requires the use
of the same DNA extraction method and purification. The use of
samples from different sources, different extraction protocols or
poor quality DNA in the same experiment is prohibitive. It is
common practice, in order to successfully perform an HRM
experiment, to analyse at least eight samples in the same batch.
To do so, all the samples included in the experiment should
derive from the same source and be processed the same way. This
limitation poses a serious problem when working in a diagnostic
laboratory, where the samples, sometimes, arrive from other
laboratories as already isolated DNA or are from different
biological sources.
The protocol we have developed allows us to analyse
consistently and with high specificity, samples from variable
sources, extracted in different ways emphasizing its application in
prenatal diagnosis. The suggested method eliminates all possible
differences between the samples allowing the accurate scanning
with minimum labour and cost. Additionally the method allows
the use of simple unlabelled probes in the second PCR reaction,
which leads to specific mutation detection (genotyping). Fig. 1
presents a flow chart of the protocol.
The major advantage of this protocol is the simultaneous
amplification of all CF regions of interest, for the specific couple,
as well as the inclusion of intragenic polymorphic markers in the
first PCR reaction. In this way we can perform direct prenatal
diagnosis by mutation detection and indirect diagnosis, if the
couple already has an affected offspring or biological material
from a previous terminated affected pregnancy, by haplotype
analysis within restrictive time limits. The diagnosis can be
completed within one working day, alleviating the parental
anxiety. After the second PCR reaction, the samples can be
retrieved and sequenced with no need for further treatment, since
the LCGreen Plus dye does not interfere with sequencing dyes.
During the development and validation of this protocol we have
included all different possible combinations of CFTR exons with
no observed failure. The results presented in this paper however,
refer to the exons most commonly analysed in our laboratory.
Although HRM should be used for genotyping only when a probe
is included in the reaction, in this protocol the use of a probe is not
essential as we know in advance the parental genotypes. However
if the expected genotypes are unknown this method can only be
used as a scanning method and further genotyping is required.
This generic protocol for prenatal diagnosis of cystic fibrosis
using HRM, has proven to be 100% efficient and specific, with
no incidence of misdiagnosis. The protocol has been validated
with retrospective analysis of 20 prenatal diagnosis cases, and
is now routinely used in our laboratory. It is our belief that this
protocol can be easily applied for other disorders. The key to
the successful implementation of such a protocol for other
disorders is the primer design. In order to achieve multiplexing,
primers should be designed so that they have the same Tms and
that no by products are formed. Such design should easily allowthe development of similar a protocol for every molecular
analysis.Appendix A. Supplementary data
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.jcf.2014.04.002.References
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